Tyra Biosciences, Inc. (TYRA): who owns it and who trades it
As of Nov 16, 2026, TYRA insiders reported 12 open-market sales worth $8.8M and 1 purchase worth $20K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert J More (Director), with $5.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tyra Biosciences
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TYRA
171 funds and institutions reported TYRA shares worth $2.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 22.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 22.65% | $390M | No change |
| FMR LLC (Fidelity) | 8.92M | 16.56% | $285M | +15% |
| Jupiter Topco LLC | 4.35M | 8.08% | $139M | – |
| Alta Partners Management Company, L.P. | 3.82M | 7.10% | $122M | No change |
| Nextech Invest Ltd. | 3.55M | 6.60% | $114M | -12% |
| TCG Crossover Management, LLC | 3.25M | 6.03% | $104M | No change |
| BlackRock, Inc. | 3.03M | 5.63% | $96.8M | +37% |
| T. Rowe Price Associates | 2.78M | 5.17% | $88.9M | +182% |
| State Street Corp | 2.14M | 3.97% | $68.4M | +76% |
| Commodore Capital LP | 1.88M | 3.48% | $59.9M | -24% |
| Paradigm Biocapital Advisors LP | 1.83M | 3.39% | $58.4M | -11% |
| Vanguard Capital Management LLC | 1.51M | 2.80% | $48.2M | +34% |
| Bvf Inc | 1.48M | 2.74% | $47.1M | -25% |
| 5AM Venture Management, LLC | 1.03M | 1.91% | $32.9M | No change |
| Deerfield Management Company, L.P. | 1.02M | 1.89% | $32.5M | +85% |
| Hood River Capital Management LLC | 1.02M | 1.89% | $32.5M | – |
| Geode Capital Management, LLC | 970,734 | 1.80% | $31M | +47% |
| Caligan Partners LP | 806,986 | 1.50% | $25.8M | -37% |
| California State Teachers Retirement System | 783,935 | 1.46% | $24.5M | – |
| Canaan Partners XI LLC | 750,000 | 1.39% | $24M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TYRA insiders reported $20K of open-market purchases and $8.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Rehan Verjee | Director | Purchase | 972 | $20.58 | $20K | Form 4 |
| Mar 25, 2026 | Gilla Kaplan | Director | Sale | 14,295 | $36.97 | $528K | Form 4 |
| Feb 12, 2026 | Daniel Bensen | Chief Discovery Officer | Sale | 2,128 | $31.50 | $67K | Form 4 |
| Feb 12, 2026 | Daniel Bensen | Chief Discovery Officer | Sale | 5,872 | $33.37 | $196K | Form 4 |
| Jan 12, 2026 | Daniel Bensen | Chief Discovery Officer | Sale | 6,983 | $28.44 | $199K | Form 4 |
| Jan 12, 2026 | Daniel Bensen | Chief Discovery Officer | Sale | 1,017 | $29.08 | $29.6K | Form 4 |
| Dec 19, 2025 | Robert J More | Director | Sale | 10,000 | $25.00 | $250K | Form 4 |
| Dec 12, 2025 | Daniel Bensen | Chief Discovery Officer | Sale | 8,000 | $22.64 | $181K | Form 4 |
| Nov 21, 2025 | Robert J More | Director | Sale | 246,871 | $20.25 | $5M | Form 4 |
| Nov 19, 2025 | Daniel Bensen | Chief Operating Officer | Sale | 49,956 | $16.32 | $815K | Form 4 |
| Nov 18, 2025 | Daniel Bensen | Chief Operating Officer | Sale | 75,633 | $16.07 | $1.2M | Form 4 |
| Nov 17, 2025 | Daniel Bensen | Chief Operating Officer | Sale | 1,500 | $17.07 | $25.6K | Form 4 |
| Nov 17, 2025 | Daniel Bensen | Chief Operating Officer | Sale | 18,572 | $16.11 | $299K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Robert J More | Director | – | $5.2M | Dec 19, 2025 |
| Daniel Bensen | Chief Operating Officer | – | $3M | Feb 12, 2026 |
| Gilla Kaplan | Director | – | $528K | Mar 25, 2026 |
| Rehan Verjee | Director | $20K | – | Sep 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TYRA short interest
High short interest. 16.6% of TYRA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.90M TYRA shares were sold short, 16.6% of the shares outstanding, up 4.3% from the report before. At the average daily volume of 647,829 shares, buying them all back would take about 15.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.90M | 16.59% | +4% | 647,829 | 15.3 |
| Oct 15, 2026 | 9.50M | 15.91% | +1% | 619,597 | 15.3 |
| Sep 30, 2026 | 9.41M | 15.77% | -5% | 1.07M | 8.8 |
| Sep 15, 2026 | 9.88M | 16.55% | +5% | 1.74M | 5.7 |
| Aug 31, 2026 | 9.44M | 15.82% | -3% | 347,850 | 27.1 |
| Aug 14, 2026 | 9.69M | 16.24% | +5% | 766,180 | 12.7 |
| Jul 31, 2026 | 9.25M | 15.49% | -7% | 518,736 | 17.8 |
| Jul 15, 2026 | 9.93M | 18.44% | -17% | 640,837 | 15.5 |
| Jun 30, 2026 | 11.92M | 22.14% | +21% | 1.27M | 9.4 |
| Jun 15, 2026 | 9.87M | 18.32% | +6% | 1.07M | 9.2 |
| May 29, 2026 | 9.28M | 17.23% | +15% | 707,583 | 13.1 |
| May 15, 2026 | 8.07M | 14.97% | +5% | 637,653 | 12.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tyra Biosciences company events
Tyra Biosciences filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 15, 2026AnnouncementTyra Biosciences, Inc. (TYRA or the Company) entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the… Filing
- Sep 9, 2026AnnouncementTyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 2, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 17, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine… Filing
- Apr 2, 2026LeadershipThe Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026. Filing
- Mar 4, 2026AnnouncementTyra Biosciences, Inc. agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Dec 1, 2025LeadershipThe Board of Directors (the Board) of Tyra Biosciences, Inc. (the Company) appointed Bhavesh Ashar as the Company’s Chief Operating Officer, succeeding Daniel Bensen in that position, who was appointed the Company’s Chief Discovery Officer, each effective as of December 1, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tyra Biosciences financials
Famous investors that hold TYRA
4 of the 50 well-known investors we track reported holding TYRA in their latest 13F filing. The largest position is Ken Griffin's, worth $3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 136,670 | $3M | 0.0% | -51% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 40,899 | $894K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 27,482 | $601K | 0.0% | -85% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 25,766 | $564K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TYRA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.8% |
Questions about Tyra Biosciences, Inc. (TYRA) stock
Who owns the most TYRA stock?
The largest reported owner of Tyra Biosciences, Inc. (TYRA) is Ra Capital Management, L.P., with 22.6% of the company. In total, 171 funds and institutions reported holding TYRA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are TYRA insiders buying or selling?
In the last 12 months, TYRA insiders reported 1 open-market purchase worth $20K and 12 sales worth $8.8M. The latest trade was on Sep 9, 2026. See every trade.
What is the short interest in TYRA?
As of Oct 30, 2026, 9.90M TYRA shares were sold short, 16.6% of the shares outstanding, up 4.3% from the report before. At the average daily volume of 647,829 shares, buying them all back would take about 15.3 trading days (days to cover). See the history.
Which famous investors hold TYRA?
4 of the 50 well-known investors we track reported TYRA in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Israel Englander. The largest position is worth $3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.